



CONTACT:
Rik J Deitsch
954-509-0911
IR@nutrapharma.com

**NUTRA PHARMA CORPORATION WILL BE PRESENTING
AT THE WALL STREET ANALYST FORUM**

Boynton Beach, FL. – February 2, 2005 - Nutra Pharma Corp., (OTCBB: NPHC) a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has today announced that its management will make a presentation to analysts and portfolio managers at The Wall Street Analyst Forum's 16th Annual NYC Analyst Conference on **Monday, February 28th at 11:40 am eastern time.**

Approximately 65 public companies will be presenting at the Conference being held at the Roosevelt Hotel on Madison Avenue at East 45th Street in New York City. Analysts and portfolio managers who wish to attend the presentation should contact The Wall Street Analyst Forum at (802)253-7596 to request additional information.

Investors may access an Internet webcast of the presentation at:

<http://www.vcall.com/CEPage.asp?ID=90209>

"We are excited at the opportunity to present the Company's business model at The Wall Street Analysts Forum," stated Rik Deitsch, Nutra Pharma's Chairman and Chief Executive Officer. "We will endeavor to communicate Nutra Pharma's current situation as well as the Company's 2005 agenda," he concluded.

About Nutra Pharma Corp.

Nutra Pharma Corporation is a biotechnology holding company and incubator. The Company's minority-owned subsidiary, ReceptoPharm, Inc, is developing technologies for the development of drugs for HIV, AMN and Multiple Sclerosis ("MS"). The Company's other holding Infectech, Inc., is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

<http://www.nutrapharma.com>

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The Company's presentation at The Wall Street Analysts Forum should not be construed as an

indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

###